276 related articles for article (PubMed ID: 23479608)
1. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells.
Liang YJ; Ding Y; Levery SB; Lobaton M; Handa K; Hakomori SI
Proc Natl Acad Sci U S A; 2013 Mar; 110(13):4968-73. PubMed ID: 23479608
[TBL] [Abstract][Full Text] [Related]
2. Glycosphingolipids in human embryonic stem cells and breast cancer stem cells, and potential cancer therapy strategies based on their structures and functions.
Liang YJ
Glycoconj J; 2022 Apr; 39(2):177-195. PubMed ID: 35267131
[TBL] [Abstract][Full Text] [Related]
3. Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype.
Liang YJ; Wang CY; Wang IA; Chen YW; Li LT; Lin CY; Ho MY; Chou TL; Wang YH; Chiou SP; Lin YJ; Yu J
Oncotarget; 2017 Jul; 8(29):47454-47473. PubMed ID: 28537895
[TBL] [Abstract][Full Text] [Related]
4. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis.
Battula VL; Shi Y; Evans KW; Wang RY; Spaeth EL; Jacamo RO; Guerra R; Sahin AA; Marini FC; Hortobagyi G; Mani SA; Andreeff M
J Clin Invest; 2012 Jun; 122(6):2066-78. PubMed ID: 22585577
[TBL] [Abstract][Full Text] [Related]
5. O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells.
Cheng JY; Hung JT; Lin J; Lo FY; Huang JR; Chiou SP; Wang YH; Lin RJ; Wu JC; Yu J; Yu AL
Front Immunol; 2021; 12():791551. PubMed ID: 35046949
[TBL] [Abstract][Full Text] [Related]
6. Glycosphingolipid expression at breast cancer stem cells after novel thieno[2,3-b]pyridine anticancer compound treatment.
Marijan S; Markotić A; Mastelić A; Režić-Mužinić N; Pilkington LI; Reynisson J; Čulić VČ
Sci Rep; 2020 Jul; 10(1):11876. PubMed ID: 32680999
[TBL] [Abstract][Full Text] [Related]
7. Fascin Is Critical for the Maintenance of Breast Cancer Stem Cell Pool Predominantly via the Activation of the Notch Self-Renewal Pathway.
Barnawi R; Al-Khaldi S; Majed Sleiman G; Sarkar A; Al-Dhfyan A; Al-Mohanna F; Ghebeh H; Al-Alwan M
Stem Cells; 2016 Dec; 34(12):2799-2813. PubMed ID: 27502039
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of Histone Methyltransferase, DOT1L, by Matrix Hyaluronan Promotes MicroRNA-10 Expression Leading to Tumor Cell Invasion and Chemoresistance in Cancer Stem Cells from Head and Neck Squamous Cell Carcinoma.
Bourguignon LY; Wong G; Shiina M
J Biol Chem; 2016 May; 291(20):10571-85. PubMed ID: 27002147
[TBL] [Abstract][Full Text] [Related]
9. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
10. Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.
Leth-Larsen R; Terp MG; Christensen AG; Elias D; Kühlwein T; Jensen ON; Petersen OW; Ditzel HJ
Mol Med; 2012 Sep; 18(1):1109-21. PubMed ID: 22692575
[TBL] [Abstract][Full Text] [Related]
11. Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047.
Cirenajwis H; Smiljanic S; Honeth G; Hegardt C; Marton LJ; Oredsson SM
Anticancer Drugs; 2010 Nov; 21(10):897-906. PubMed ID: 20838207
[TBL] [Abstract][Full Text] [Related]
12. Role of microRNAs in the regulation of breast cancer stem cells.
Liu S; Clouthier SG; Wicha MS
J Mammary Gland Biol Neoplasia; 2012 Mar; 17(1):15-21. PubMed ID: 22331423
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics.
Shao J; Fan W; Ma B; Wu Y
Mol Med Rep; 2016 Dec; 14(6):4991-4998. PubMed ID: 27840965
[TBL] [Abstract][Full Text] [Related]
14. NMI inhibits cancer stem cell traits by downregulating hTERT in breast cancer.
Feng X; Xu X; Xiao X; Zou K; Yu W; Wu J; Tang R; Gao Y; Hao J; Zhao X; Liao Y; Chen Y; Huang W; Guo W; Kang L; Deng W
Cell Death Dis; 2017 May; 8(5):e2783. PubMed ID: 28492540
[TBL] [Abstract][Full Text] [Related]
15. Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation.
Louie E; Nik S; Chen JS; Schmidt M; Song B; Pacson C; Chen XF; Park S; Ju J; Chen EI
Breast Cancer Res; 2010; 12(6):R94. PubMed ID: 21067584
[TBL] [Abstract][Full Text] [Related]
16. Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer.
Cho Y; Lee HW; Kang HG; Kim HY; Kim SJ; Chun KH
Oncotarget; 2015 Apr; 6(11):8709-21. PubMed ID: 25909162
[TBL] [Abstract][Full Text] [Related]
17. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
18. miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation.
Bahena-Ocampo I; Espinosa M; Ceballos-Cancino G; Lizarraga F; Campos-Arroyo D; Schwarz A; Maldonado V; Melendez-Zajgla J; Garcia‐Lopez P
EMBO Rep; 2016 May; 17(5):648-58. PubMed ID: 27113763
[TBL] [Abstract][Full Text] [Related]
19. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
20. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]